BTdCPU
| CAS No. | 1257423-87-2 | Cat. No. | BCP31242 |
| Name | BTdCPU | ||
| Synonyms | eIF2–GTP–tRNAiMetTernaryCompInhib,BTdCPU; | ||
| Formula | C13H8Cl2N4OS | M. Wt | 339.19 |
| Description | BTdCPU is an activator of HRI. The eIF2-alpha kinase HRI is a novel therapeutic target in multiple myeloma. Combination therapy with rapamycin, an mTOR inhibitor, and BTdCPU, an activator of HRI, demonstrated additive effects on apoptosis in dex-resistant cells. Thus, specific activation of the eIF2α kinase HRI is a novel therapeutic target in MM that can augment current treatment strategies. | ||
| Pathways | Cell Cycle/DNA Damage | ||
| Targets | eIF | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.